Conatus announces top-line results from ENCORE-NF phase 2b clinical trial in NASH fibrosis

The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72. “Although emricasan did not have the

The post Conatus announces top-line results from ENCORE-NF phase 2b clinical trial in NASH fibrosis appeared first on Pharmaceutical Business review.

GSK’s anti-BCMA antibody-drug conjugate improves ORR in cancer study

The further positive data from the DREAMM-1 study, which is based on results of the pre-specified interim analysis, showed the durability and depth of response of GSK2857916 anti-BCMA

The post GSK’s anti-BCMA antibody-drug conjugate improves ORR in cancer study appeared first on Pharmaceutical Business review.

Imago BioSciences announces $40m Series B financing led by Omega Funds

Other investors participating in the round include existing investors Frazier Healthcare Partners, Amgen Ventures, and MRL Ventures Fund as well as HighLight Capital, Pharmaron and Greenspring Associates. Dr.

The post Imago BioSciences announces $40m Series B financing led by Omega Funds appeared first on Pharmaceutical Business review.

Study suggests epigenetic protein as new therapeutic target in AML

A group of researchers at the Cambridge Institute for Medical Research found that the epigenetic protein delayed the development of AML. However, the epigenetic protein was found to

The post Study suggests epigenetic protein as new therapeutic target in AML appeared first on Pharmaceutical Business review.

Merck, NGM Bio extend multi-year strategic collaboration

The collaboration, originally announced in February 2015, is focused on discovering, developing and commercializing novel biologic therapeutics across a wide range of therapeutic areas. Under the terms of

The post Merck, NGM Bio extend multi-year strategic collaboration appeared first on Pharmaceutical Business review.

Pfizer secures option to buy Vivet Therapeutics in €560m deal

Pfizer has paid around €45m ($51m) to purchase a 15% equity interest in Vivet Therapeutics, and will pay up to €560m that includes option exercise payment and certain

The post Pfizer secures option to buy Vivet Therapeutics in €560m deal appeared first on Pharmaceutical Business review.

Mundipharma launches Invokana and Vokanamet in Norway for treatment of type 2 diabetes

In line with the partnership with Janssen Pharmaceutica NV, Mundipharma now exclusively distributes and markets these treatments across 18 countries in the European Economic Area (EEA) and Switzerland.

The post Mundipharma launches Invokana and Vokanamet in Norway for treatment of type 2 diabetes appeared first on Pharmaceutical Business review.

Merck KGaA, Pfizer discontinue phase III JAVELIN ovarian PARP 100 trial

The alliance has notified health authorities and trial investigators of the decision to discontinue the trial. The decision was based on several emerging factors since the trial’s initiation,

The post Merck KGaA, Pfizer discontinue phase III JAVELIN ovarian PARP 100 trial appeared first on Pharmaceutical Business review.

Evotec, GARDP partner to tackle antimicrobial resistance threat

The public-private partnership between Evotec and GARDP will strive to address the increasing threat of antimicrobial resistance (AMR). It will combine GARDP’s clinical expertise and Evotec’s drug discovery

The post Evotec, GARDP partner to tackle antimicrobial resistance threat appeared first on Pharmaceutical Business review.

Sage Therapeutics gets FDA nod for Zulresso to treat postpartum depression

Zulresso is claimed to be the first and only medicine secured approval to treat PPD, which is the most common medical complication of childbirth. The medicine is an

The post Sage Therapeutics gets FDA nod for Zulresso to treat postpartum depression appeared first on Pharmaceutical Business review.